Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anadys Resumes Work With TLR7 Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

HCV candidate’s preclinical toxicity resolved, but investor focus is still mainly on polymerase inhibitor.

You may also be interested in...



GSK’s Responds To FDA On Cervarix, Will Augment BLA With More Efficacy Data

Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.

Merck’s Heplisav Gets FDA Clinical Hold

Phase III subject diagnosed with Wegener’s granulomatosis, a rare blood vessel inflammation.

Merck KGaA Joins Rush To Develop Toll-Like Receptor 9 Agonists

Company signed a deal with Idera valued at $421 million, gaining two of its lead TLR9 candidates for oncology indications, excluding vaccines.

Related Content

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel